AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05789277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training program
Description: Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging
Study NCT05789277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring training
Description: Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
Study NCT06265935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
Study NCT06046677 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04113291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Diet
Description: 12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
Study NCT04113291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: 12 weeks usual diet \<2300 mg Na/day
Study NCT05598060 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
Description: Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
Study NCT04779762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's disease exclusion diet (CDED)
Description: Dietary therapy for Crohn's disease
Study NCT04779762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Injection [Stelara]
Description: Drug for Crohn's disease
Study NCT04779762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab Injection [Stelara]
Description: Drug for Crohn's disease
Study NCT06514911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary closure following Laparoscopic cholodochotomy in management of CBD stones
Description: primary closure of cholodochotomy incision in laparoscopic CBD exploration avoiding T-tube insertion
Study NCT06514911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones
Description: drainage of bile by T-tube insertion in laparpscopic CBD exploration
Study NCT05276908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar interfascial plane block (TLIP)Technique
Description: A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
Study NCT05276908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthetic Management
Description: Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position.
Study NCT05276908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection 10ml
Description: patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
Study NCT05276908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection 20ml
Description: patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
Study NCT05169593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Biological Drug
Description: Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
Study NCT05169593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biological Drug
Description: Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
Study NCT05684718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100 (300 mg)
Description: Intravenous solution
Study NCT05684718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Oral solution
Study NCT04781413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-PTX, Sintilimab, S-1
Description: This is a single-arm study with all patients receiving these three drugs.
Study NCT05597787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Connect
Description: online education and clinical skills
Study NCT05597787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ECHO for HIV Prevention
Description: education and clinical skills
Study NCT05597787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ECHO for HIV Prevention and Stigma Reduction
Description: education, clinical skills and contact
Study NCT06484920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: 150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
Study NCT06484920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W pembrolizumab
Study NCT05920720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Personalized Treatment
Description: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Study NCT05000931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia 2 System
Description: Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
Study NCT04747197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal injection
Study NCT06194487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50mL) per day
Study NCT06194487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAXI Collagen drink
Description: consume 1 bottle (50mL) per day
Study NCT06194487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fish collagen drink
Description: consume 1 bottle (50mL) per day
Study NCT05435469 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
Study NCT05988567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo candy
Description: consume 2 tablets per day
Study NCT05988567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melon and oil olive pressed candy
Description: consume 2 tablets per day
Study NCT05015036 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS
Description: Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
Study NCT05015036 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Classic Minimally invasive surgery of the lumbar spine
Study NCT06225973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-925
Description: TL-925 is an eye drop.
Study NCT06225973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
Study NCT05724303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week neuromuscular training program
Description: Training program consisting of two neuromuscular training sessions per week
Study NCT05208333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Albenza 200Mg Tablet
Description: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection
Study NCT04858308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC506
Description: YYC506
Study NCT04858308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Active control
Study NCT04858308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC506 Placebo
Description: Placebo
Study NCT04858308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Placebo
Description: Placebo
Study NCT05088499 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study NCT05946200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow technique in general anesthesia
Description: It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
Study NCT05946200 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low flow technique in general anesthesia
Description: It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
Study NCT06203470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Description: Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
Study NCT06203470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: topical Calcineurin inhibitor
Study NCT04718870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study NCT05766774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-added sugar, high-fat diet
Description: Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
Study NCT05766774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-added sugar, high-fat CF diet
Description: Consist of ≥13% kcal from added sugars and the glycemic index will be >60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
Study NCT05578274 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + LDRT
Description: SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV.
Study NCT05578274 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT alone
Description: SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.
Study NCT05419024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Treatment Interruption
Description: Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
Study NCT06724887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Strategy Training and Education
Description: Initial training strategies cover Strategic Memory Advanced Reasoning Tactics (SMART), and subsequent training extends the SMART principles to other life-applications such as stress management, sleep, and lifestyle. Virtual and in-person workshops will expand on topics such as stress management, sleep, resilience, and mental well-being, with an emphasis on how practicing and implementing brain healthy strategies can impact everyday life. For faculty/staff, we will also offer interactive workshops on how to create a brain healthy environment and classroom, including ways to implement and provide brain-healthy strategies and resources in their everyday operations involving students.
Study NCT06727708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tone Your Body BioCircuit Program
Description: Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.
Study NCT06727708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boost Performance BioCircuit Program
Description: Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
Study NCT06729008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes-specific nutrition formula (DSNF)
Description: The diabetes-specific nutrition formula to be used in this study will be Glucerna (Abbott Laboratories). It features an advanced blend of low-glycemic carbohydrates for steady energy release, a dual fiber blend to support digestive health, and a unique lipid blend free from trans fats, cholesterol, and low in saturated fat. Additionally, Glucerna is enriched with 4x more inositol and high levels of trivalent chromium, which contribute to maintaining normal blood glucose levels. It provides 28 essential vitamins and minerals, is low in lactose, and gluten-free, making it a suitable option for various dietary needs. 5 scoops will be mixed in 200 mL of water, and this amounts to 228 calories, with 30.01g of carbohydrates, 10.16g of protein, and 8.70g of fat. This will be given twice, as a breakfast replacement and an afternoon snack replacement.
Study NCT06729008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy
Description: Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
Study NCT06729008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therapy
Description: Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
Study NCT06180642 — intervention group
Intervention type: OTHER
Intervention: Assessment of soft tissue properties
Description: Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
Study NCT05556148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otrivine Congestion Relief
Description: 0.1% Nasal Spray (Xylometazoline Hydrochloride)
Study NCT05102669 — intervention group
Intervention type: OTHER
Intervention: analysis of immunological response
Description: collection and analysis of SARS-CoV2 Spike specific blood cells
Study NCT05102669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of serum antibodies
Description: analysis of anti-SARS-CoV2 Spike specific antibodies
Study NCT04994561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drugs and Nutritional Supplements
Description: Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months.
Study NCT06410716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valve-regulated pleural drainage system
Description: Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
Study NCT05946226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC002 injection
Description: three different IMC002 Doses will be escalated in 3+3 design
Study NCT05695742 — intervention group
Intervention type: OTHER
Intervention: Active Smoking
Description: Being active smoker
Study NCT05695742 — intervention group
Intervention type: OTHER
Intervention: Passive smoker
Description: Being exposed to secondhand smoke
Study NCT06180642 — intervention group
Intervention type: OTHER
Intervention: Retest assessment of soft tissue properties
Description: Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
Study NCT05695742 — intervention group
Intervention type: OTHER
Intervention: Non-smoker
Description: Not being an active or passive smoker.
Study NCT06432972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehab
Description: Prehab will include 2, one-hour sequential sessions of PR per day as is standard, however this intervention will increase the frequency from 2 days to 4 days per week, for 2 weeks, thus completing 16 sessions of PR prior to surgery. An exercise prescription will be written by the medical director based on initial 6MWD, age, height, weight, and co-morbidities, as is standard of care. Prior to each session, patients are evaluated for symptoms and vital signs are measured. Exercise will include 30 minutes of warm-up and upper and lower extremity resistance training, either against gravity or with resistance bands as appropriate. Exercise will then move to the open gym, where patients utilize endurance equipment of their choosing, such as a treadmill or recumbent bicycle. As with traditional PR, participants will be given online education videos regarding lung health to complete at home, with a supplementary video on breathing techniques to reduce atelectasis from pain.
Study NCT04761367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity. Physical Activity program is performed in a group in a gym
Description: The intervention groups will be trained in a gyms under the direct supervision of a graduate trainer. All subjects will be requested to choose an additional third day of the week to carry out at least one of the following activities: walking, cycling or swimming